Clinical Trials Directory

Trials / Completed

CompletedNCT06917040

Enhancing Protection Against Vector-borne Diseases in Forcibly Displaced Communities: Evaluating the Efficacy of Spatial Repellents for Cutaneous Leishmaniasis Control in North-East Syria

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
18,404 (actual)
Sponsor
The Mentor Initiative · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

The aim of this study is to determine the efficacy of Mosquito Shield (spatial repellent) in reducing cutaneous leishmaniasis case incidence among internally displaced persons and sandfly density in temporary shelters and camp settings in Ar-Raqqa governorate, North-East Syria.

Conditions

Interventions

TypeNameDescription
DEVICESpatial repellant emanatorSpatial emanator with an active ingredient Transfluthrin (C15H12Cl2F4O2, 110mg, EPA registered number 432-1588).

Timeline

Start date
2021-02-01
Primary completion
2022-04-01
Completion
2022-04-01
First posted
2025-04-08
Last updated
2025-04-08

Locations

1 site across 1 country: Syria

Source: ClinicalTrials.gov record NCT06917040. Inclusion in this directory is not an endorsement.